Nephros Inc (NEPH) Cotización

NEPH under $3

new CEO has a lot of relevant experience... stock free cash flow positive for the first time since 2019,barely

IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!

Tony Robinson appointed VP of Operations

Did anyone conduct an interview???

Former COO of CVR Medical Corp.

CVR is embroiled in a complete melt down including Months Long Trading Halt, Regulator Complaints, Officer and Board Resignations, etc. etc...

Check it out yourselves.
https://investorshub.advfn.com/CVR-Medical-CRRVF-31902/

Will it be same path for Nephros??

Good luck too all... But you know there is no such thing as luck. Do you???


https://www.google.com/url?rct=j&sa=t&url=https://finance.yahoo.com/news/specialty-renal-products-announces-appointment-113010721.html&ct=ga&cd=CAEYACoTNjQ4NzgzMTcxODY0ODE3NTM5OTIaZmMwMWYzNzEzMDg5NzBkZTpjb206ZW46VVM&usg=AFQjCNFLK2fj0BSn9_cTYMzGog-9d3292Q

TIMBER! 493,827 Shares of NEPH Common Stock declared effective by the SEC and are now freely trading after the 6 month lock-up agreement ends November 15, 2019


https://www.otcmarkets.com/filing/html?id=13688528&guid=2q-SUaH2vzeKx3h#FORM424B3_HTM_A_006

News: $NEPH Nephros Announces Preliminary Financial Results for Third Quarter 2019

Anticipates $3.1 Million Product Revenue, 85% Growth Over 2018 Increases Full-Year Revenue Guidance to $9.5-10 Million SOUTH ORANGE, NJ, Oct. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells hi...

Find out more NEPH - Nephros Announces Preliminary Financial Results for Third Quarter 2019

I think it should be five cents. I will buy several hundred shares at five cents per share.

i think they call that putting lipstick on a pig.

NEPH moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

08/14/2019 01:46:03 Market Center Change Listed on NASDAQ
08/14/2019 01:46:03
NEPH
Nephros, Inc. Common Stock

NEPH one for 9 reverse split. PPS closed at .62.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

It should be five cents. Once it gets to five cents I will buy up to 792 shares, but not before it gets to five cents.

I think it should be five cents. I bid five cents per share for a full 150 shares.

News: $NEPH Nephros Announces Preliminary Financial Results for First Quarter 2019

Anticipates $1.7 Million Revenue; Year-over-Year Growth Exceeds 75% SOUTH ORANGE, NJ, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device and commercial products company that develops and sells high performance wa...

Read the whole news https://marketwirenews.com/news-releases/nephros-announces-preliminary-financial-results-for-first-quarter-2019-7962048.html

Dilution. Retest the lows.

NEPH Chart Looking Nice

Nephros Inc. to present at The Microcap Conference.

SeeThruEquity Issues Update on Nephros (NEPH) with Target Price of $1.80

https://finance.yahoo.com/news/seethruequity-issues-nephros-neph-target-140000345.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANmMzVsMGp0ZGE1djg5BGcDZFhWcFpEeHVjejR5TldJeVpURm1NQzB5T0RnMUxUTmhZVEF0T0dZMVpTMWhPV0kzWlRZNU56WTBZelYxZFdsa1BHNXpQazVGVUVnPQ0KBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuBG9yaWdfcmVnaW9uA1VTBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDTkVQSA--?.tsrc=applewf

Some action here today. Nice move up on decent volume.

Still buying this

Surprised it hasn’t moved..... this could be a sleeper

Nephros Announces Preliminary Financial Results for Fourth Quarter 2017
Jan 04, 2018
OTC Disclosure & News Service

-

Anticipates Over 80% Year-over-Year Product Revenue Growth for the Quarter

SOUTH ORANGE, NJ, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced preliminary financial results for the fourth quarter of 2017.

Nephros expects product revenue for the fourth quarter ended December 31, 2017, to be approximately $1,258,000, an increase of approximately 83% over the same period in 2016. Total revenue for the quarter ended December 31, 2017 is projected to exceed $1,300,000, an increase of more than 75% over the same period in 2016.

Net cash used in operating activities for the fourth quarter 2017 is expected to be approximately $38,000 including approximately $65,000 of cash paid for interest on outstanding notes. Nephros ended the quarter with approximately $2.2 million in cash.

“While we have a long way to go to reach our full potential, we continue to gain traction in the market with our product offerings and to successfully compete for large, multi-year filtration contracts,” said Daron Evans, CEO of Nephros. “In addition to solid quarterly revenue growth and a strong year-end cash balance, we were essentially cash flow neutral from an operational basis this quarter. For 2018, we foresee a continuation of our growth in medical filter sales, an expansion of our commercial and industrial filter sales, and the ability to invest proceeds into our second generation HDF system.”

Holding the line....

So far it looks like sellers are not giving in. That's a good sign. Hang in there guys

Definitely looks like they are heading into a rapid growth stage. Could certainly end up being a short term 4-bagger for those buying now.

Seems like they are over a huge hurdle.

Revenue of $915,000?

Now this is based on sales and has nothing to do with the tax credits or selling their operating loses correct?

>>>
The Company expects total revenue for the third quarter ending September 30, 2017 of approximately $915,000, an increase of approximately 95% over the same period in 2016. Based upon the anticipated sales trajectory, the Company believes that it can be sustainably cash flow positive around the end of 2017.

Still here for a very long time

I'm surprised no one is talking about NEPH. They claim to be cash flow positive in the next few months and short interest has declined slightly.

Anyone here?

Conf coming up

http://finance.yahoo.com/news/nephros-announces-participation-18th-annual-113000293.html

She's tryin

LezzzzGo

Ughh

NEPH bullish 0.38

So are the filters selling?

What were you short? Lol

Ugh...

Roll on NEPH

Finally someone noticed. Good price action today, with some volume. Stock is too much under the radar.

NEPHROS RECEIVES FDA 510(K) CLEARANCE OF S100 POINT OF USE FILTER
RIVER EDGE, NJ, April 14, 2016– Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its S100 Point of Use filter designed to filter Environmental Protection Agency (“EPA”) quality drinking water to retain waterborne bacteria to assist in infection control.
The S100 ultrafilter is designed to assist hospitals and medical facilities with their efforts to protect patients from water-borne bacteria. Legionella and Pseudomonas are common bacteria that can have a devastating impact on infected patients, particularly those whose immune system is compromised. The S100 Point of Use filter attaches to the end of a sink faucet and is designed to provide up to 3 months of protection.
“In response to customer feedback, the S100 adds an end of faucet product to our infection control portfolio to support hospitals in their efforts to protect patients from water-borne pathogens,” said Daron Evans, President and CEO of Nephros. “With the 510(k) process completed, we intend to fill initial orders for S100 filters this quarter.”
About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.
For more information about Nephros, please visit the company’s website at www.nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the S100, including the timing of filling initial orders for such product, and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, the availability of capital when needed, our dependence on third party manufacturers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2015. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

Contact:

Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com
POST NAVIGATION
? Nephros Reports 2015 Fourth Quarter and Full Year Financial Results; Provides 2016 Guidance and Potential Upcoming Milestones
×
Close
HOME
DIALYSIS
INFECTION CONTROL
HDF
PRODUCT RESOURCES
PRESS
TEAM
CORPORATE GOVERNANCE
INVESTOR RELATIONS
CONTACT



HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

DIALYSIS FILTERS
BETTER WATER = IMPROVED PATIENT WELLBEING
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›
1
2
3
4
5
6
7
8
9
10
11
PrevNext
1
2
3
4
5
6
7
8
9
PrevNext
1
2
3
4
5
6
7
PrevNext
1
2
3
4
5
PrevNext
1
2
3
PrevNext

DIALYSIS CLINICS

DIALYSIS ULTRAFILTERS

HEMODIAFILTRATION SYSTEMS
HOSPITAL

INFECTION CONTROL ULTRAFILTERS
INDUSTRIAL

COMMERCIAL ULTRAFILTERS

LATEST NEWS

04/14/2016
Nephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
03/30/2016
Nephros Reports 2015 Fourth Quarter and Full Year Financial Results; Provides 2016 Guidance and Potential Upcoming Milestones
03/16/2016
Nephros Launches SSUmini and Provides S100 Update
VIEW PRESS RELEASE ARCHIVES>
UPCOMING EVENTS

QUICK LINKS

Partner Links
Commercial Product Downloads
FDA-cleared Product Downloads
VIEW ALL RESOURCES >

For Customer Service and Product Information
Email: filters@nephros.com
Call: (201) 343-5202
DIALYSIS ULTRAFILTERS
DSU-D
SSU-D
HEMODIAFILTRATION
OLpur® H2H Hemodiafiltration Module
OLpur® MD220 Hemodiafilter
INFECTION CONTROL
Ice Machines
Showers
Sinks
INDUSTRIAL
Coming Soon
COMPANY
Home
Upcoming Events
Press Releases
Contact Us
Investor Relations

© Copyright 2016 Nephros, Inc. | All Rights Reserved
41 Grand Ave. River Edge, NJ 07661 Tel: 201.343.5202 Fax: 201.343.5207 info@nephros.com

Nephros Launches SSUmini and Provides S100 Update

Mar 16, 2016 07:30:00 (ET)

RIVER EDGE, N.J.--(BUSINESS WIRE)--March 16, 2016--
Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF") system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announces the release of the SSUmini, a smaller version of its SSU-D medical device.

SSUmini Launch

The SSUmini was developed as a compact, economical solution to provide hemodialysis quality water as a polish filter for smaller, portable reverse osmosis ("RO") systems and to provide hemodialysis quality bicarbonate concentrate for dialysis clinics with centralized bicarbonate systems. For low-flow rate situations, the SSUmini can provide protection from bacteria, viruses and endotoxins for up to 12 months. The SSUmini is a medical device with U.S. Food and Drug Administration ("FDA") 510(k) clearance. Details on the SSUmini can be found at www.nephros.com/dialysis.

"We have been working with multiple dialysis water system suppliers and have identified an area where we believe our filter technology could add additional value," said Monet Carnahan, Director of Dialysis Products at Nephros. "The SSUmini is small enough to fit inside most portable RO systems, enabling our partners to supply the product as an OEM part. It also provides a low-cost, long-life polish filter for those dialysis clinics that centrally mix their bicarbonate concentrate."

The SSU-10 is also now available. The SSU-10 is ideal as a polish filter for smaller RO systems, either on the laboratory benchtop or in the home setting under the sink. The SSU-10 is not a medical device.

S100 510(k) Update

The Company filed for 510(k) clearance for its S100 Point of Use microfilter with the FDA in late October 2015. In late December 2015, the FDA requested additional information. On March 8, 2016, the Company submitted a package to the FDA with supplemental information. Pending FDA clearance, the Company aims to launch the S100 in the second quarter of 2016.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the timing of the Company's responses to the FDA relating to its 510(k) submission for its S100 product; feedback from customers regarding our new products; the timing of planned deliveries of products to the Company's distributors and partners; our plans to expand our product line, our expectations related to the receipt of FDA clearance on new products; our plan to expand into additional market segments; our plan to grow revenues sufficient to generate positive cash flow, and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, uncertainties in the FDA clearance process, the acceptance of our product offerings by customers and end users, and the availability of sufficient capital to fund our operating activities. These and other risks and uncertainties are detailed in Nephros Inc.'s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

View source version on businesswire.com: www.businesswire.com/news/home/20160316005289/en/


CONTACT: Investor:
PCG Advisory Group

Kirin M. Smith, 646-863-6519

Chief Operating Officer

www.pcgadvisory.com


SOURCE: Nephros, Inc.
Copyright Business Wire 2016

(END) Dow Jones Newswires

March 16, 2016 07:30 ET (11:30 GMT)

Multiple product lines based on proprietary filtration technology
- Ultrafilters for dialysis water and bicarbonate
- Ultrafilters to aid in infection control in hospitals
- Hemodiafiltration systems to provide dialysis for end stage renal patients
• Ultrafilter business unit has $100M+ revenue potential:
- Distributor-based sales model into dialysis clinics and hospitals
- ASHRAE 188-2015, a recently approved industry guideline that is
generating high-levels of focus on waterborne pathogen protection
- Multiple partnering opportunities for ultrafilters as OEM components
• Hemodiafiltration (HDF) System business unit has $100M+ revenue
potential with minimal market penetration
- 4% market share of dialysis patients = $100M in revenue from
disposables from HDF system
• Royalties and profit sharing from license to CamelBak® in Military
Recreation market

Great buy in for the this stock....

Great buy in point....

Big things in the work at NEPH

2016 going to be strong for NEPH